Why Eliquis is Often Preferred Over Xarelto for Atrial Fibrillation Patients

Why Eliquis is Often Preferred Over Xarelto for Atrial Fibrillation Patients

For individuals with atrial fibrillation (AFib), anticoagulants are vital for reducing the risk of stroke and blood clots. Eliquis (apixaban) and Xarelto (rivaroxaban) are among the most popular options, both belonging to the class of direct oral anticoagulants (DOACs). Although both medications are effective, evidence from clinical studies indicates that Eliquis may offer additional benefits for AFib patients, particularly in terms of bleeding risk, stroke prevention, and tolerability.

Below, we explore the research findings comparing Eliquis and Xarelto, helping explain why Eliquis is frequently preferred for certain AFib patients. Always consult with a healthcare provider, as they will determine the best anticoagulation option based on individual patient needs and risks.

1. Lower Risk of Major Bleeding with Eliquis

One of the primary concerns with anticoagulants is the risk of major bleeding, a potentially serious complication. Research shows that Eliquis may have a lower bleeding risk than Xarelto, which is particularly beneficial for elderly patients or those predisposed to bleeding.

  • ARISTOTLE Trial: This pivotal study compared Eliquis with warfarin and found that Eliquis reduced major bleeding by 31% compared to warfarin, making it a safer option for patients with bleeding risks. In contrast, the XANTUS study, which evaluated Xarelto, reported higher rates of major bleeding compared to similar studies on Eliquis . This demonstrates that Eliquis may be a safer option for AFib patients who need to minimize bleeding complications.

These findings underscore Eliquis’s safety profile, particularly for patients at an increased risk of bleeding.

2. Superior Efficacy in Stroke Prevention

For AFib patients, the main goal of anticoagulation is to reduce the risk of ischemic stroke due to blood clots. Studies indicate that Eliquis may offer a slight advantage over Xarelto in stroke prevention.

  • Stroke Prevention: Head-to-head comparisons and meta-analyses have shown that Eliquis has lower rates of stroke and systemic embolism compared to Xarelto, potentially offering better protection against these serious outcomes .

  • Consisteance Across Trials: Eliquis consistently outperformed warfarin in terms of stroke prevention, while Xarelto’s results were generally comparable to warfarin rather than surpassing it, giving Eliquis a slight efficacy edge .

3. Twice-Daily Dosing Offers Steadier Blood Levels

Eliquis is administered twice daily, while Xarelto is taken once daily. Although twice-daily dosing may seem less convenient, it offers steadier blood levels and potentially more consistent protection.

  • Steady Blood Levels: With twice-daily dosing, Eliquis maintains stable anticoagulant levels in the bloodstream, reducing peaks and troughs that could otherwise increase bleeding or clotting risks. In contrast, Xarelto’s once-daily dosing can lead to fluctuations that some patients may find problematic.

Many healthcare providers view Eosing schedule as a favorable factor for patients requiring constant blood-thinning effects.

Comparing Eliquis and Xarelto for safer anticoagulation in AFib patients

4. Improved Tolerability and Adherence

Studies show that Eliquis tends to be better tolerated than Xarelto, with fewer reported side effects. This can lead to improved adherence, which is crucial for long-term success in anticoagulation therapy.

  • Reduced Gastrointestinal Side Effects: Patients on Eliquis generally report fewer gastrointestinal issues, such as nausea or stomach discomfort, compared to those on Xarelto. This can make Eliquis more comfortable, especially for patients sensitive to GI side effects.

  • Lower Discontinuation Rates: Due to its favorable side effect profile, patients taking Eliquis are less likely to discontinue treatment, helping ensure consistent anticoagulation and stroke prevention.

Why Eliquis is safer than Xarelto for patients with kidney issues and AFib

5. Safer Option for Patients with Kidney Disease

Patients with kidney impairment need careful management when using anticoagulants. Eliquis is generally safer than Xarelto for these patients due to how it works:

  • Reduced Dependence on Kidneys: Eliquis has less reliance on renal excretion than Xarelto, making it a better choice for those with reduced kidney function.

  • Customizable Dosing: Eliquis offers specific dose adjustments for patients with kidney disease, helping to lower bleeding risk while maintaining effectiveness. Xarelto’s dose adjustments may not be as effective in these cases.

Cost-Saving Option: Buy Eliquis from Canada

While Eliqen favored for its safety and efficacy, it can be costly. U.S. patients may find substantial savings by purchasing Eliquis from Canadian pharmacies. In Canada, drug prices are regulated, allowing patients to save up to 50% compared to U.S. prices.

For additional savings, some patients may also consider the generic version of apixaban available in Canada, which offers the same active ingredient at an even lower cost.

Conclusion: Why Eliquis Is Often Preferred Over Xarelto

Eliquis is frequently considered superior to Xarelto for AFib patients, offering lower bleeding risks, more effective stroke prevention, and better tolerability. These advantages, combined with the potential for cost savings through Canadian pharmacies, make Eliquis a compelling choice for patients requiring anticoagulation therapy. Always consult with your healthcare provider, as they will make the best recommendation based on your health profile, lifestyle, and individual risks.

For more information on Eliquis and its benefits, visit the official Eliquis website.

References

  1. American College of Cardiology Guidelines on Anticoagulation for AFib Patients. ACC
  2. National Institutes of Health, ARISTOTLE and XANTUS Study Summaries. NIH
  3. Journal of the American Medical Association on Eliquis vs. Xarelto Outcomes. JAMA